Catalyst (CPRX) Reports Q3 Earnings: What Key Metrics Have to Say

Core Insights - Catalyst Pharmaceutical (CPRX) reported a revenue of $128.7 million for the quarter ended September 2024, reflecting a year-over-year increase of 25.3% [1] - The earnings per share (EPS) for the quarter was $0.57, a significant improvement from -$0.24 in the same quarter last year [1] - The reported revenue exceeded the Zacks Consensus Estimate of $122.97 million by 4.65%, and the EPS surpassed the consensus estimate of $0.49 by 16.33% [1] Revenue Breakdown - Product revenue from FIRDAPSE was $79.30 million, exceeding the average estimate of $77.60 million from five analysts [3] - Total product revenue was $126.42 million, compared to the five-analyst average estimate of $122.93 million [3] - Product revenue from AGAMREE reached $15.05 million, surpassing the average estimate of $10.99 million [3] - Product revenue from FYCOMPA was $32.08 million, slightly below the average estimate of $34.34 million [3] Stock Performance - Catalyst's shares have returned +9.4% over the past month, outperforming the Zacks S&P 500 composite, which saw a change of +0.7% [4] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [4]